1. US Department of Health and Human Services Food and Drug Administration. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. CFR. 2010.
2. US Department of Health and Human Services Food and Drug Administration. Safety reporting requirements for INDs and BA/BE Studies. Guidance for industry and investigators. 2012.
3. US Department of Health and Human Services Food and Drug Administration. Safety assessment for IND safety reporting. Draft guidance for industry. 2015.
4. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994;50:337–349.
5. Ball G. Continuous safety screens for randomized controlled clinical trials with blinded treatment information [PhD dissertation]. Houston: University of Texas, School of Public Health; 2008.